About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NAMS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 28, 2026Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's…
NCT07794670 · Preclinical Alzheimer's Disease
Obicetrapib 10 mg, Matching placebo tablets
NAMS
NewAmsterdam Pharma
Phase 2Recruiting400Sep 2028Registry ↗
Sep 9, 2026A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib…
NCT07219602 · Lipidemia, Type 2 Diabetes (T2DM)
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib…
NAMS
NewAmsterdam Pharma
Phase 3Active, not recruiting300Mar 2028Registry ↗
Apr 9, 2026Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NCT06496243 · Dyslipidemias
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
NAMS
NewAmsterdam Pharma
Phase 2Recruiting69Nov 2026Registry ↗
Apr 9, 2026A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
NCT06305559 · Lipidemia, Coronary Artery Disease
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Placebo
NAMS
NewAmsterdam Pharma
Phase 3Active, not recruiting300Nov 2027Registry ↗
Oct 20, 2025Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
NCT06982508 · Antioxidant Absorption
Obicetrapib 10mg, Placebo
NAMS
NewAmsterdam Pharma
Phase 2Recruiting100Sep 2026Registry ↗
Oct 8, 2025Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying…
NCT06005597 · Dyslipidemias, Hypercholesterolemia
Combination Therapy, Monotherapy obicetrapib
NAMS
NewAmsterdam Pharma
Phase 3Completed407Sep 25, 2024Registry ↗
Sep 19, 2025Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying…
NCT05142722 · Dyslipidemias, High Cholesterol
Placebo, Obicetrapib
NAMS
NewAmsterdam Pharma
Phase 3Completed2,530Sep 26, 2024Registry ↗
Jun 11, 2025Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifyin…
NCT05425745 · Dyslipidemias, High Cholesterol
Obicetrapib, Placebo
NAMS
NewAmsterdam Pharma
Phase 3Completed354May 28, 2024Registry ↗
May 22, 2025A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvast…
NCT06081166 · Healthy Volunteers
Obicetrapib, Atorvastatin Calcium
NAMS
NewAmsterdam Pharma
Phase 1Completed74Dec 2, 2023Registry ↗
Jan 29, 2025Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
NCT05161715 · Early Alzheimer's Disease
Obicetrapib
NAMS
NewAmsterdam Pharma
Phase 2Completed13May 9, 2023Registry ↗
Nov 14, 2024A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy…
NCT06547359 · Healthy Volunteers
Obicetrapib 10mg, Ezetimibe 10mg
NAMS
NewAmsterdam Pharma
Phase 1Completed94Nov 12, 2024Registry ↗
Oct 29, 2024A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to St…
NCT05421078 · Dyslipidemia, Hypercholesterolemia
Obicetrapib, Placebo
NAMS
NewAmsterdam Pharma
Phase 2Completed102Mar 24, 2023Registry ↗
Sep 19, 2024Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
NCT06250205 · Healthy Volunteers
Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol…
NAMS
NewAmsterdam Pharma
Phase 1Completed30Apr 25, 2024Registry ↗
Sep 19, 2024PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Norma…
NCT06048302 · Hepatic Impairment, Healthy
Obicetrapib
NAMS
NewAmsterdam Pharma
Phase 1Completed18Mar 12, 2024Registry ↗
Sep 19, 2024Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
NCT05972278 · Lipid Metabolism
Obicetrapib
NAMS
NewAmsterdam Pharma
Phase 1Unknown22Sep 26, 2024Registry ↗
Jul 12, 2024Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
NCT04753606 · Dyslipidemias, High Cholesterol
Obicetrapib
NAMS
NewAmsterdam Pharma
Phase 2Completed120May 24, 2021Registry ↗
Jul 3, 2024Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Ther…
NCT05266586 · Dyslipidemias, High Cholesterol
Obicetrapib, Ezetimibe 10mg
NAMS
NewAmsterdam Pharma
Phase 2Completed119Aug 12, 2022Registry ↗
Jun 5, 2024Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib…
NCT06050291 · Healthy Volunteer Study
Fixed-Dose Combination (FDC) Tablet
NAMS
NewAmsterdam Pharma
Phase 1Completed28Apr 7, 2024Registry ↗
Jun 4, 2024Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular…
NCT05202509 · Atherosclerotic Cardiovascular Disease
Obicetrapib, Placebo
NAMS
NewAmsterdam Pharma
Phase 3Active, not recruiting9,541Nov 2026Registry ↗
Apr 24, 2024Randomized Study of Obicetrapib in Combination With Ezetimibe
NCT04770389 · Dyslipidemias, High Cholesterol
Obicetrapib 5mg, Ezetimibe 10mg
NAMS
NewAmsterdam Pharma
Phase 2Completed112May 7, 2021Registry ↗

20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:02 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances